As a primary interface between the radiopharmacy community and regulatory authorities, the group aims to provide a common understanding of regulatory requirements for clinical trials that involve radiopharmaceuticals.
CERT has the key aim of acting as the primary interface between the radiopharmacy community and regulatory authorities.
The emphasis is on creating a common understanding of the regulatory requirements for the development and delivery of clinical trials that involve radiopharmaceuticals, primarily at ECMCs but also all other relevant UK clinical trial units.
CERT actively influences clinical trial regulations and guidelines to take into account the specialised nature of radiopharmacy clinical trials. This helps ensure that coherent implementation into practice happens across the UK radiopharmacy community.
Kim Orchard (University Hospital Southampton)
MembersPei-San Chan (Royal Free Hospital)Margaret Cooper (Royal Liverpool Hospital)Jilly Croasdale (Birmingham City Hospital NHS Trust)Glenn Flux (Institute of Cancer Research)Adam McMahon (University of Manchester)Sam Mowbray (University of Manchester)Maria Palmer (United Bristol Healthcare NHS Trust)James Ritchie (Cancer Research UK)Julie Silvester (Cancer Research UK)Nigel Westwood (Cancer Research UK)
No Resources found
The Experimental Cancer Medicine Centre initiative is jointly funded by Cancer Research UK, the National Institute for Health Research in England and the Departments of Health for Scotland, Wales and Northern Ireland.